Literature DB >> 11964920

Cystic fibrosis.

Amanda L Brennan1, Duncan M Geddes.   

Abstract

Cystic fibrosis is the most common lethal inherited disorder with autosomal recessive inheritance. Major progress has been made in understanding the molecular mechanisms leading to increased susceptibility to Pseudomonas aeruginosa colonization. Persistent respiratory infection with P. aeruginosa leads to progressive pulmonary inflammation and is the major cause of morbidity and mortality. Treatment and prophylaxis of respiratory infection has improved the median survival and quality of life of cystic fibrosis patients. In the future, treatment of the underlying genetic defect may be possible.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11964920     DOI: 10.1097/00001432-200204000-00013

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  20 in total

1.  The Pseudomonas aeruginosa Chp chemosensory system regulates intracellular cAMP levels by modulating adenylate cyclase activity.

Authors:  Nanette B Fulcher; Phillip M Holliday; Erich Klem; Martin J Cann; Matthew C Wolfgang
Journal:  Mol Microbiol       Date:  2010-03-16       Impact factor: 3.501

2.  DNA binding: a novel function of Pseudomonas aeruginosa type IV pili.

Authors:  Erin J van Schaik; Carmen L Giltner; Gerald F Audette; David W Keizer; Daisy L Bautista; Carolyn M Slupsky; Brian D Sykes; Randall T Irvin
Journal:  J Bacteriol       Date:  2005-02       Impact factor: 3.490

3.  Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis.

Authors:  Maria Entezari; Daniel J Weiss; Ravikumar Sitapara; Laurie Whittaker; Matthew J Wargo; JianHua Li; Haichao Wang; Huan Yang; Lokesh Sharma; Binh D Phan; Mohammad Javdan; Sangeeta S Chavan; Edmund J Miller; Kevin J Tracey; Lin L Mantell
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

4.  Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis.

Authors:  J Kirk Harris; Mary Ann De Groote; Scott D Sagel; Edith T Zemanick; Robert Kapsner; Churee Penvari; Heidi Kaess; Robin R Deterding; Frank J Accurso; Norman R Pace
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

5.  Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis.

Authors:  V Raia; L Maiuri; C Ciacci; I Ricciardelli; L Vacca; S Auricchio; M Cimmino; M Cavaliere; M Nardone; A Cesaro; J Malcolm; S Quaratino; M Londei
Journal:  Thorax       Date:  2005-06-30       Impact factor: 9.139

6.  The effect of a bacteriophage on diversification of the opportunistic bacterial pathogen, Pseudomonas aeruginosa.

Authors:  Michael A Brockhurst; Angus Buckling; Paul B Rainey
Journal:  Proc Biol Sci       Date:  2005-07-07       Impact factor: 5.349

Review 7.  Novel molecular approaches to cystic fibrosis gene therapy.

Authors:  Tim W R Lee; David A Matthews; G Eric Blair
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

8.  Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.

Authors:  Heinz Arnold; Dirk Bumann; Melanie Felies; Britta Gewecke; Meike Sörensen; J Engelbert Gessner; Joachim Freihorst; Bernd Ulrich von Specht; Ulrich Baumann
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

9.  Azithromycin retards Pseudomonas aeruginosa biofilm formation.

Authors:  Richard J Gillis; Barbara H Iglewski
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

10.  Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis.

Authors:  Christopher R Sudfeld; Elliott C Dasenbrook; William G Merz; Karen C Carroll; Michael P Boyle
Journal:  J Cyst Fibros       Date:  2009-12-31       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.